- Home
- BHC vs IDYA Comparison
BHC vs IDYA Comparison
Compare BHC & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHC
- IDYA
- Stock Information
- Founded
- BHC N/A
- IDYA 2015
- Country
- BHC Canada
- IDYA United States
- Employees
- BHC N/A
- IDYA N/A
- Industry
- BHC Biotechnology: Pharmaceutical Preparations
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- BHC Health Care
- IDYA Health Care
- Exchange
- BHC Nasdaq
- IDYA Nasdaq
- Market Cap
- BHC 2.5B
- IDYA 2.1B
- IPO Year
- BHC N/A
- IDYA 2019
- Fundamental
- Price
- BHC $7.78
- IDYA $24.05
- Analyst Decision
- BHC Hold
- IDYA Strong Buy
- Analyst Count
- BHC 2
- IDYA 13
- Target Price
- BHC $9.00
- IDYA $51.36
- AVG Volume (30 Days)
- BHC 4.4M
- IDYA 1.1M
- Earning Date
- BHC 07-30-2025
- IDYA 08-05-2025
- Dividend Yield
- BHC N/A
- IDYA N/A
- EPS Growth
- BHC N/A
- IDYA N/A
- EPS
- BHC 0.27
- IDYA N/A
- Revenue
- BHC $9,858,000,000.00
- IDYA $7,000,000.00
- Revenue This Year
- BHC $5.53
- IDYA $101.44
- Revenue Next Year
- BHC $3.70
- IDYA $263.37
- P/E Ratio
- BHC $29.39
- IDYA N/A
- Revenue Growth
- BHC 7.13
- IDYA N/A
- 52 Week Low
- BHC $4.25
- IDYA $13.45
- 52 Week High
- BHC $9.85
- IDYA $40.74
- Technical
- Relative Strength Index (RSI)
- BHC 65.68
- IDYA 53.53
- Support Level
- BHC $5.68
- IDYA $22.09
- Resistance Level
- BHC $8.69
- IDYA $25.11
- Average True Range (ATR)
- BHC 0.43
- IDYA 1.20
- MACD
- BHC 0.20
- IDYA -0.04
- Stochastic Oscillator
- BHC 71.47
- IDYA 52.55
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.